Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
SXTP · Nasdaq · United States · Pharmaceutical Preparations
In short60 DEGREES PHARMACEUTICALS, INC. is loss-making, burns cash and holds more cash than debt, with revenue growing (+65.5% last year).
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | -771.6% | 0/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -732.5% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -196.4% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | -214.6% | 0/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 2.66× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.04× | 100/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | Net cash | 100/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | -994.05× | 0/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | -33.25 | 0/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | -695.1% | 0/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 0 of 4 | 0/100 |
Weight in the score: 20%
| Profitable years (last 5) | 0 of 4 | 0/100 |
|---|---|---|
| Years of revenue decline (last 5) | 0 of 3 | 100/100 |
| Revenue growth volatility | 63.3% | 0/100 |
| Operating margin volatility | 624.9% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 65.2% | 100/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
The last 4 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Revenue | 0.2 | 0.3 | 0.6 | 1 |
| Cost of revenue | 0.4 | 0.5 | 0.4 | 0.8 |
| Gross profit | (0.2) | (0.2) | 0.2 | 0.2 |
| Research & development | 0.5 | 0.7 | 5 | 2.1 |
| Operating income | (1.8) | (5.2) | (9.7) | (7.8) |
| Interest expense | 4 | 2.3 | 0 | 0 |
| Pre-tax income | (6.2) | (3.8) | (8) | (7.4) |
| Income tax | 0 | 0 | 0 | 0 |
| Net income | (6.2) | (3.8) | (7.9) | (7.4) |
| Diluted EPS | −$2.61 | −$59.18 | −$74.17 | −$11.73 |
| Diluted shares (millions) | 2.4 | 0.1 | 0.1 | 0.7 |
−33.25 Distress zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
3/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Aug 14, 2026